Dalia Barsyte-Lovejoy

Dalia Barsyte-Lovejoy

SGC Toronto

Barsyte-Lovejoy

Biography

Dr. Dalia Barsyte-Lovejoy, PhD is an Assistant Professor at the Department of Pharmacology and Toxicology, UofT, and Principal Investigator at the SGC-Toronto, working to understand fundamental regulatory mechanisms of epigenetic proteins and their pharmacological modulation in cancer. The group’s research focuses on disease mechanisms, therapeutic targets, and chemical probe discovery, resulting in over 30 extensively characterized compounds that have helped shape the emerging field of epigenetics and enabled over 50 collaborative projects that are uncovering new epigenetic mechanisms in cancer and its treatment.

Research Areas

We are interested in understanding the mechanism of epigenetic regulators and posttranslational modifications that control cancer cell growth, differentiation, and therapy response. Protein lysine and arginine methyltransferases regulate transcription, genome stability, splicing, RNA metabolism, and other cell processes dictated by which substrates these enzymes methylate. Lysine methyltransferases such as EZH2 and NSD2 primarily methylate histones to establish repressive and active chromatin. In contrast, arginine methyltransferases have a broad scope of substrates ranging from histones to signaling molecules, enzymes, and structural proteins. Epigenetic chromatin regulation, transcriptome, and cellular signaling are fine-tuned by ubiquitin modification. Our work seeks to understand how these posttranslational modifications are misregulated in cancer and identify new therapeutic targets.

Through multidisciplinary research that includes cell and chemical biology, protein structural biology, and many collaborative studies with colleagues across industry and academia, the SGC chemical probes project has generated several probes for methyltransferases, ubiquitin ligases, and deubiquitylases. We are currently using these chemical probes to explore the cellular pathways in poor prognosis acute myeloid leukemia, pancreatic, lung and breast cancer.

 Epigenetics, chromatin and cellular signaling regulators

Epigenetics and chromatin architecture regulators


 

 

 

Epigenetics is about how the DNA code is regulated. Proteins that bind/modify DNA and histones play essential roles in cell identity determination, transcription, and genome maintenance. They are often responsible for diseases such as cancer or uncontrolled inflammation.

We are studying how epigenetic proteins regulate normal cell processes and how these are subverted in disease. 

 

Chemical probes as tools for cancer target discovery


 

Chemical probes as tools for cancer target discovery

 

To study epigenetic modifier proteins, we need genetic and pharmacological tools. Chemical probe compounds that potently and selectively inhibit or degrade the target proteins in cells provide tools for modulating activating/repressing histone marks and other cellular signaling pathways. By discovering and using chemical probes, we expand our understanding of the protein function and its therapeutic utility to establish a biological rationale in cancer therapy.

 

 

 

Link to Open Lab notebooks that features science community posts on our various projects https://openlabnotebooks.org/

2023

Discovery and Characterization of BAY-805, a Potent and Selective Inhibitor of Ubiquitin-Specific Protease USP21.

Göricke F, Vu V, Smith L, Scheib U, Böhm R, Akkilic N, Wohlfahrt G, Weiske J, Bömer U, Brzezinka K, Lindner N, Lienau P, Gradl S, Beck H, Brown PJ, Santhakumar V, Vedadi M, Barsyte-Lovejoy D, Arrowsmith CH, Schmees N, Petersen K

J Med Chem. 2023-2-20 . .doi: 10.1021/acs.jmedchem.2c01933

PMID: 36802665

2022

Skeletal muscle metabolism and contraction performance regulation by teneurin C-terminal-associated peptide-1.

Hogg DW, Reid AL, Dodsworth TL, Chen Y, Reid RM, Xu M, Husic M, Biga PR, Slee A, Buck LT, Barsyte-Lovejoy D, Locke M, Lovejoy DA

Front Physiol. 2022-12-17 . 13:1031264 .doi: 10.3389/fphys.2022.1031264

PMID: 36523555

Combinatorial Anticancer Drug Screen Identifies Off-Target Effects of Epigenetic Chemical Probes.

Barghout SH, Mann MK, Aman A, Yu Y, Alteen MG, Schimmer AD, Schapira M, Arrowsmith CH, Barsyte-Lovejoy D

ACS Chem Biol. 2022-9-9 . .doi: 10.1021/acschembio.2c00451

PMID: 36084291

Enzymatic nucleosome acetylation selectively affects activity of histone methyltransferases in vitro.

Trush VV, Feller C, Li ASM, Allali-Hassani A, Szewczyk MM, Chau I, Eram MS, Jiang B, Luu R, Zhang F, Barsyte-Lovejoy D, Aebersold R, Arrowsmith CH, Vedadi M

Biochim Biophys Acta Gene Regul Mech. 2022-7-27 . 194845 .doi: 10.1016/j.bbagrm.2022.194845

PMID: 35907431

Chemical biology and pharmacology of histone lysine methylation inhibitors.

Barghout SH, Machado RAC, Barsyte-Lovejoy D

Biochim Biophys Acta Gene Regul Mech. 2022-6-23 . 194840 .doi: 10.1016/j.bbagrm.2022.194840

PMID: 35753676

PRMT inhibition induces a viral mimicry response in triple-negative breast cancer.

Wu Q, Nie DY, Ba-Alawi W, Ji Y, Zhang Z, Cruickshank J, Haight J, Ciamponi FE, Chen J, Duan S, Shen Y, Liu J, Marhon SA, Mehdipour P, Szewczyk MM, Dogan-Artun N, Chen W, Zhang LX, Deblois G, Prinos P, Massirer KB, Barsyte-Lovejoy D, Jin J, De Carvalho DD, Haibe-Kains B, Wang X, Cescon DW, Lupien M, Arrowsmith CH

Nat Chem Biol. 2022-5-16 . .doi: 10.1038/s41589-022-01024-4

PMID: 35578032

Validating Small Molecule Chemical Probes for Biological Discovery.

Vu V, Szewczyk MM, Nie DY, Arrowsmith CH, Barsyte-Lovejoy D

Annu Rev Biochem. 2022-4-1 . .doi: 10.1146/annurev-biochem-032620-105344

PMID: 35363509

PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade.

Srour N, Villarreal OD, Hardikar S, Yu Z, Preston S, Miller WH, Szewczyk MM, Barsyte-Lovejoy D, Xu H, Chen T, Del Rincón SV, Richard S

Cell Rep. 2022-3-29 . 38(13):110582 .doi: 10.1016/j.celrep.2022.110582

PMID: 35354055

PRMT5 regulates ATF4 transcript splicing and oxidative stress response.

Szewczyk MM, Luciani GM, Vu V, Murison A, Dilworth D, Barghout SH, Lupien M, Arrowsmith CH, Minden MD, Barsyte-Lovejoy D

Redox Biol. 2022-3-11 . 51:102282 .doi: 10.1016/j.redox.2022.102282

PMID: 35305370